Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
André J. Scheen. (2023) Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update. Expert Opinion on Drug Metabolism & Toxicology 19:8, pages 543-553.
Read now
Read now
Rianne A. Weersink, David M. Burger, Kelly L. Hayward, Katja Taxis, Joost P.H. Drenth & Sander D. Borgsteede. (2020) Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations. Expert Opinion on Drug Metabolism & Toxicology 16:1, pages 45-57.
Read now
Read now
Hidayat Hussain, Ivan R. Green, Iftikhar Ali, Ikhlas A. Khan, Zulfiqar Ali, Abdullah M. Al-Sadi & Ishtiaq Ahmed. (2017) Ursolic acid derivatives for pharmaceutical use: a patent review (2012-2016). Expert Opinion on Therapeutic Patents 27:9, pages 1061-1072.
Read now
Read now
Christoph G. Dietrich, Monika Rau, Daniel Jahn & Andreas Geier. (2017) Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease. Expert Opinion on Drug Metabolism & Toxicology 13:6, pages 625-640.
Read now
Read now
André J Scheen. (2015) Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 1005-1020.
Read now
Read now
Martha Gonzalez, Laura Goracci, Gabriele Cruciani & Italo Poggesi. (2014) Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease. Expert Opinion on Drug Metabolism & Toxicology 10:10, pages 1397-1408.
Read now
Read now
Articles from other publishers (37)
Anne-Sofie H. Jensen, Henriette Ytting, Marie Winther-Sørensen, Johan Burisch, Annika Bergquist, Lise Lotte Gluud & Nicolai J. Wewer Albrechtsen. (2023) Autoimmune liver diseases and diabetes. European Journal of Gastroenterology & Hepatology 35:9, pages 938-947.
Crossref
Crossref
Laurent Castera & Kenneth Cusi. (2023) Diabetes and cirrhosis: Current concepts on diagnosis and management. Hepatology 77:6, pages 2128-2146.
Crossref
Crossref
Fu-Shun Yen, Ming-Chih Hou, James Cheng-Chung Wei, Ying-Hsiu Shih, Chung Y. Hsu, Chih-Cheng Hsu & Chii-Min Hwu. (2023) Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes. Clinical Gastroenterology and Hepatology.
Crossref
Crossref
Maxime Mallet, Cristina Alina Silaghi, Philippe Sultanik, Filomena Conti, Marika Rudler, Vlad Ratziu, Dominique Thabut & Raluca Pais. (2023) Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis. Hepatology.
Crossref
Crossref
Md. Salam, Md. Rana, Prodip Baral, Md. Rahman, Shaheen Ahmed, Rubiya Rahman, Nusaiba Jahan, Tanoy Mazumder, Mohammad Islam & Md. Hussain. (2023) Glipizide has Low Influences on Lipid Index and Major Organs Weight Variation and Considerable Anxiolytic Properties: An in vivo Investigation. Journal of Medical Sciences 23:1, pages 7-17.
Crossref
Crossref
Fu-Shun Yen, Ming-Chih Hou, Jia-Sin Liu, Chih-Cheng Hsu & Chii-Min Hwu. (2023) Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes. Frontiers in Medicine 9.
Crossref
Crossref
Maria Letizia Petroni, Lucia Brodosi & Giulio Marchesini. (2023) The treatment of diabetes in advanced liver disease: change of a paradigm. Annals of Hepatology 28:1, pages 100772.
Crossref
Crossref
Fu-Shun Yen, Ming-Chih Hou, Chun-Wei Pan, Jia-Sin Liu, Chih-Cheng Hsu & Chii-Min Hwu. (2022) The Risk of Severe Hypoglycemia and Mortality in Patients With Type 2 Diabetes and Discharged With Acute Liver Injury. Diabetes Care.
Crossref
Crossref
Chia-Yen Dai, Tzu-Jung Fang, Wei-Wen Hung, Hui-Ju Tsai & Yi-Chun Tsai. (2022) The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Biomedicines 10:7, pages 1487.
Crossref
Crossref
Lucia Brodosi, Salvatore Petta, Maria L. Petroni, Giulio Marchesini & Maria C. Morelli. (2021) Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients. Transplantation 106:3, pages 462-478.
Crossref
Crossref
Pankaj Puri & Narendra Kotwal. (2022) An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist. Journal of Clinical and Experimental Hepatology 12:2, pages 560-574.
Crossref
Crossref
Fu-Shun Yen, Chih-Cheng Hsu, James Cheng-Chung Wei, Ming-Chih Hou & Chii-Min Hwu. (2022) Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease. Frontiers in Medicine 9.
Crossref
Crossref
Jörg Bojunga & Mireen Friedrich-Rust. (2021) Diabetestherapie bei fortgeschrittenen Lebererkrankungen und LeberzirrhoseDiabetes treatment in advanced liver disease and liver cirrhosis. Der Diabetologe 18:1, pages 26-35.
Crossref
Crossref
Jerome Boursier, Rodolphe Anty, Claire Carette, Bertrand Cariou, Laurent Castera, Cyrielle Caussy, Helene Fontaine, Armand Garioud, Pierre Gourdy, Bruno Guerci, Maeva Guillaume, Niasha Michot, Anne Minello, Dann J Ouizeman, Lawrence Serfaty, Fabrice Bonnet, Bruno Vergès & Jean-Michel Petit. (2021) Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. Diabetes & Metabolism 47:5, pages 101272.
Crossref
Crossref
Fu-Shun Yen, Jung-Nien Lai, James Cheng-Chung Wei, Lu-Ting Chiu, Chii-Min Hwu, Ming-Chih Hou & Chih-Cheng Hsu. (2020) Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis. PLOS ONE 15:12, pages e0243783.
Crossref
Crossref
Kelly L. Hayward & Rianne A. Weersink. (2020) Improving Medication‐Related Outcomes in Chronic Liver Disease. Hepatology Communications 4:11, pages 1562-1577.
Crossref
Crossref
Jörg Bojunga. (2020) Diabetestherapie bei nichtalkoholischer Fettlebererkrankung und LeberzirrhoseDiabetes therapy in nonalcoholic fatty liver disease and liver cirrhosis. Der Gastroenterologe 15:2, pages 96-105.
Crossref
Crossref
Eun Yi Cho, Jee-Yeon Ryu, Han A. Reum Lee, Shin Hee Hong, Hye Sun Park, Kwan Soo Hong, Sang-Gyu Park, Hong Pyo Kim & Tae-Jong Yoon. (2019) Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes. Journal of Nanobiotechnology 17:1.
Crossref
Crossref
R. Chawla, B. M. Makkar, S. Aggarwal, S. Bajaj, A. K. Das, S. Ghosh, A. Gupta, S. Gupta, S. Jaggi, J. Jana, J. Keswadev, S. Kalra, P. Keswani, V. Kumar, A. Maheshwari, A. Moses, C. L. Nawal, J. Panda, V. Panikar, G. D. Ramchandani, P. V. Rao, B. Saboo, R. Sahay, K. R. Setty, V. Viswanathan, SR Aravind, S Banarjee, A Bhansali, HB Chandalia, S Das, OP Gupta, S Joshi, A Kumar, KM Kumar, SV Madhu, A Mittal, V Mohan, C Munichhoodappa, A Ramachandran, BK Sahay, J Sai, V Seshiah & AH Zargar. (2019) RSSDI consensus recommendations on insulin therapy in the management of diabetes. International Journal of Diabetes in Developing Countries 39:S2, pages 43-92.
Crossref
Crossref
Athanasia Papazafiropoulou & Andreas Melidonis. (2019) Antidiabetic agents in patients with hepatic impairment. World Journal of Meta-Analysis 7:8, pages 380-388.
Crossref
Crossref
Matteo Tacelli, Ciro Celsa, Bianca Magro, Aurora Giannetti, Grazia Pennisi, Federica Spatola & Salvatore Petta. (2018) Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. Pharmaceuticals 11:4, pages 121.
Crossref
Crossref
Chia-Ter Chao, Jui Wang, Jenq-Wen Huang & Kuo-Liong Chien. (2018) Acarbose Use and Liver Injury in Diabetic Patients With Severe Renal Insufficiency and Hepatic Diseases: A Propensity Score-Matched Cohort Study. Frontiers in Pharmacology 9.
Crossref
Crossref
Chunmei Xu, Junyu Zhao, Xiaojun Zhou, Rui Zhang, Tianyue Xie, Zhiwei Zou, Lin Liao & Jianjun Dong. (2018) Thiazolidinediones versus metformin on improving abnormal liver enzymes in patients with type 2 diabetes mellitus: a meta-analysis. Oncotarget 9:15, pages 12389-12399.
Crossref
Crossref
L. Yu. Morgunov. (2017) DIABETES MELLITUS IN PATIENTS WITH LIVER CIRRHOSIS: NEW TREATMENT OPTIONS. Research'n Practical Medicine Journal 4:3, pages 75-85.
Crossref
Crossref
André J. Scheen. (2016) Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. Clinical Pharmacokinetics 56:7, pages 703-718.
Crossref
Crossref
Chalermrat Bunchorntavakul & K. Rajender Reddy. (2017) Drug Hepatotoxicity. Clinics in Liver Disease 21:1, pages 115-134.
Crossref
Crossref
Nobuya Inagaki, Wayne H.-H. Sheu, David R. Owens, Susanne Crowe, Amit Bhandari, Yan Gong & Sanjay Patel. (2016) Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials. Journal of Diabetes and its Complications 30:8, pages 1622-1630.
Crossref
Crossref
Joan S. Grant & Lucinda J. Graven. (2016) Progressing From Metformin to Sulfonylureas or Meglitinides. Workplace Health & Safety 64:9, pages 433-439.
Crossref
Crossref
André J. Scheen. (2016) Precision medicine: The future in diabetes care?. Diabetes Research and Clinical Practice 117, pages 12-21.
Crossref
Crossref
Filomena S. G. Silva, Paulo J. Oliveira & Maria F. Duarte. (2016) Oleanolic, Ursolic, and Betulinic Acids as Food Supplements or Pharmaceutical Agents for Type 2 Diabetes: Promise or Illusion?. Journal of Agricultural and Food Chemistry 64:15, pages 2991-3008.
Crossref
Crossref
Diego García-Compeán, José Alberto González-González, Fernando Javier Lavalle-González, Emmanuel Irineo González-Moreno, Jesús Zacarías Villarreal-Pérez & Héctor J. Maldonado-Garza. (2015) Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy. Digestive Diseases and Sciences 61:2, pages 371-380.
Crossref
Crossref
Diego García-Compeán, José Alberto González-González, Fernando Javier Lavalle-González, Emmanuel Irineo González-Moreno, Jesús Zacarías Villarreal-Pérez & Héctor Jesús Maldonado-Garza. (2016) Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?. World Journal of Gastroenterology 22:10, pages 2869.
Crossref
Crossref
Diego García-Compeán, José A. González-González, Fernando J. Lavalle-González, Emmanuel I. González-Moreno, Héctor J. Maldonado-Garza & Jesús Z. Villarreal-Pérez. (2015) The treatment of diabetes mellitus of patients with chronic liver disease. Annals of Hepatology 14:6, pages 780-788.
Crossref
Crossref
Wenguang ChangLi ChenGrant M. Hatch. (2015) Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochemistry and Cell Biology 93:5, pages 479-486.
Crossref
Crossref
John D. Clarke, Anika L. Dzierlenga, Nicholas R. Nelson, Hui Li, Samantha Werts, Michael J. Goedken & Nathan J. Cherrington. (2015) Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis. Diabetes 64:9, pages 3305-3313.
Crossref
Crossref
Jingye Zhou, Jianfeng Xu, Zheng Huang & Minmin Wang. (2015) Transporter-mediated tissue targeting of therapeutic molecules in drug discovery. Bioorganic & Medicinal Chemistry Letters 25:5, pages 993-997.
Crossref
Crossref
André J. Scheen. (2014) Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus. Clinical Pharmacokinetics 53:9, pages 773-785.
Crossref
Crossref